GlassScriptPhysician profile
David J Salinger
NPI 1861495996
$1,213.76
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $453 · 2022: $277.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $342.27 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $232.28 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $213.99 | 2022 | |
| Astellas Pharma US INC | $137.17 | 2019-2020 | |
| Abbvie INC. | $124.42 | 2019 | |
| Pfizer INC. | $44.74 | 2019 | |
| Ferring Pharmaceuticals INC. | $29.09 | 2019-2020 | |
| Clinigen, INC. | $26.13 | 2019-2020 | |
| Pharmacosmos Therapeutics INC. | $24.70 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $21.59 | 2020 | |
| Eisai INC. | $17.38 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Salinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.